nodes	percent_of_prediction	percent_of_DWPC	metapath
Trazodone—ABCB1—Mitomycin—urinary bladder cancer	0.148	0.324	CbGbCtD
Trazodone—CYP3A4—Thiotepa—urinary bladder cancer	0.067	0.147	CbGbCtD
Trazodone—CYP3A5—Etoposide—urinary bladder cancer	0.0466	0.102	CbGbCtD
Trazodone—ABCB1—Gemcitabine—urinary bladder cancer	0.0425	0.0932	CbGbCtD
Trazodone—ABCB1—Cisplatin—urinary bladder cancer	0.0309	0.0677	CbGbCtD
Trazodone—ABCB1—Etoposide—urinary bladder cancer	0.0303	0.0666	CbGbCtD
Trazodone—ABCB1—Doxorubicin—urinary bladder cancer	0.0207	0.0454	CbGbCtD
Trazodone—ABCB1—Methotrexate—urinary bladder cancer	0.02	0.044	CbGbCtD
Trazodone—CYP2D6—Doxorubicin—urinary bladder cancer	0.0195	0.0428	CbGbCtD
Trazodone—CYP3A4—Etoposide—urinary bladder cancer	0.0182	0.0399	CbGbCtD
Trazodone—CYP3A4—Doxorubicin—urinary bladder cancer	0.0124	0.0272	CbGbCtD
Trazodone—HTR2A—urine—urinary bladder cancer	0.00456	0.0628	CbGeAlD
Trazodone—CYP3A4—urine—urinary bladder cancer	0.00422	0.0581	CbGeAlD
Trazodone—CYP2D6—urine—urinary bladder cancer	0.00415	0.0572	CbGeAlD
Trazodone—ORM1—prostate gland—urinary bladder cancer	0.00363	0.05	CbGeAlD
Trazodone—ADRA1A—prostate gland—urinary bladder cancer	0.00253	0.0348	CbGeAlD
Trazodone—HTR2B—smooth muscle tissue—urinary bladder cancer	0.00217	0.0299	CbGeAlD
Trazodone—CYP3A5—prostate gland—urinary bladder cancer	0.00202	0.0278	CbGeAlD
Trazodone—ORM1—female reproductive system—urinary bladder cancer	0.00198	0.0273	CbGeAlD
Trazodone—HRH1—prostate gland—urinary bladder cancer	0.00196	0.027	CbGeAlD
Trazodone—ADRA2A—prostate gland—urinary bladder cancer	0.00192	0.0265	CbGeAlD
Trazodone—HTR1A—renal system—urinary bladder cancer	0.00187	0.0258	CbGeAlD
Trazodone—ADRA1A—epithelium—urinary bladder cancer	0.00186	0.0256	CbGeAlD
Trazodone—HTR2C—female reproductive system—urinary bladder cancer	0.00178	0.0245	CbGeAlD
Trazodone—ADRA1A—renal system—urinary bladder cancer	0.00173	0.0237	CbGeAlD
Trazodone—SLC6A4—female reproductive system—urinary bladder cancer	0.00169	0.0232	CbGeAlD
Trazodone—HTR2B—female reproductive system—urinary bladder cancer	0.00167	0.023	CbGeAlD
Trazodone—ADRA2A—seminal vesicle—urinary bladder cancer	0.00163	0.0224	CbGeAlD
Trazodone—HTR2B—vagina—urinary bladder cancer	0.00151	0.0208	CbGeAlD
Trazodone—HRH1—epithelium—urinary bladder cancer	0.00144	0.0198	CbGeAlD
Trazodone—HRH1—smooth muscle tissue—urinary bladder cancer	0.00139	0.0191	CbGeAlD
Trazodone—CYP3A5—renal system—urinary bladder cancer	0.00138	0.0189	CbGeAlD
Trazodone—HRH1—urethra—urinary bladder cancer	0.00131	0.0181	CbGeAlD
Trazodone—ADRA2A—urethra—urinary bladder cancer	0.00129	0.0177	CbGeAlD
Trazodone—HTR2A—epithelium—urinary bladder cancer	0.0012	0.0166	CbGeAlD
Trazodone—ORM1—lymph node—urinary bladder cancer	0.00116	0.016	CbGeAlD
Trazodone—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00116	0.016	CbGeAlD
Trazodone—HTR2A—renal system—urinary bladder cancer	0.00112	0.0154	CbGeAlD
Trazodone—ABCB1—prostate gland—urinary bladder cancer	0.00107	0.0148	CbGeAlD
Trazodone—HRH1—female reproductive system—urinary bladder cancer	0.00107	0.0147	CbGeAlD
Trazodone—ADRA2A—female reproductive system—urinary bladder cancer	0.00105	0.0145	CbGeAlD
Trazodone—CYP3A4—renal system—urinary bladder cancer	0.00103	0.0142	CbGeAlD
Trazodone—CYP2D6—renal system—urinary bladder cancer	0.00102	0.014	CbGeAlD
Trazodone—CYP3A5—vagina—urinary bladder cancer	0.000996	0.0137	CbGeAlD
Trazodone—HTR2B—lymph node—urinary bladder cancer	0.000978	0.0135	CbGeAlD
Trazodone—HRH1—vagina—urinary bladder cancer	0.000967	0.0133	CbGeAlD
Trazodone—ADRA2A—vagina—urinary bladder cancer	0.00095	0.0131	CbGeAlD
Trazodone—ABCB1—seminal vesicle—urinary bladder cancer	0.000907	0.0125	CbGeAlD
Trazodone—HTR2A—female reproductive system—urinary bladder cancer	0.000893	0.0123	CbGeAlD
Trazodone—CYP3A4—female reproductive system—urinary bladder cancer	0.000827	0.0114	CbGeAlD
Trazodone—CYP2D6—female reproductive system—urinary bladder cancer	0.000814	0.0112	CbGeAlD
Trazodone—HTR2A—vagina—urinary bladder cancer	0.000808	0.0111	CbGeAlD
Trazodone—ABCB1—epithelium—urinary bladder cancer	0.000788	0.0108	CbGeAlD
Trazodone—ABCB1—renal system—urinary bladder cancer	0.000731	0.0101	CbGeAlD
Trazodone—ABCB1—urethra—urinary bladder cancer	0.000718	0.00988	CbGeAlD
Trazodone—HRH1—lymph node—urinary bladder cancer	0.000626	0.00861	CbGeAlD
Trazodone—ADRA2A—lymph node—urinary bladder cancer	0.000614	0.00846	CbGeAlD
Trazodone—ABCB1—female reproductive system—urinary bladder cancer	0.000585	0.00806	CbGeAlD
Trazodone—ABCB1—vagina—urinary bladder cancer	0.000529	0.00729	CbGeAlD
Trazodone—Dyspnoea—Cisplatin—urinary bladder cancer	0.000423	0.00103	CcSEcCtD
Trazodone—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000422	0.00103	CcSEcCtD
Trazodone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000421	0.00103	CcSEcCtD
Trazodone—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00042	0.00102	CcSEcCtD
Trazodone—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000419	0.00102	CcSEcCtD
Trazodone—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000418	0.00102	CcSEcCtD
Trazodone—Anorexia—Etoposide—urinary bladder cancer	0.000415	0.00101	CcSEcCtD
Trazodone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000414	0.00101	CcSEcCtD
Trazodone—Decreased appetite—Cisplatin—urinary bladder cancer	0.000413	0.00101	CcSEcCtD
Trazodone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000413	0.00101	CcSEcCtD
Trazodone—Drowsiness—Methotrexate—urinary bladder cancer	0.000409	0.000996	CcSEcCtD
Trazodone—Hypotension—Etoposide—urinary bladder cancer	0.000407	0.000991	CcSEcCtD
Trazodone—Pain—Cisplatin—urinary bladder cancer	0.000406	0.00099	CcSEcCtD
Trazodone—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000403	0.000982	CcSEcCtD
Trazodone—Dizziness—Thiotepa—urinary bladder cancer	0.000401	0.000977	CcSEcCtD
Trazodone—Urticaria—Fluorouracil—urinary bladder cancer	0.000398	0.00097	CcSEcCtD
Trazodone—Pollakiuria—Epirubicin—urinary bladder cancer	0.000396	0.000966	CcSEcCtD
Trazodone—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000396	0.000966	CcSEcCtD
Trazodone—Sweating—Methotrexate—urinary bladder cancer	0.000392	0.000955	CcSEcCtD
Trazodone—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000392	0.000954	CcSEcCtD
Trazodone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000391	0.000954	CcSEcCtD
Trazodone—Paraesthesia—Etoposide—urinary bladder cancer	0.000391	0.000953	CcSEcCtD
Trazodone—Weight increased—Epirubicin—urinary bladder cancer	0.00039	0.000952	CcSEcCtD
Trazodone—Haematuria—Methotrexate—urinary bladder cancer	0.00039	0.00095	CcSEcCtD
Trazodone—Weight decreased—Epirubicin—urinary bladder cancer	0.000388	0.000946	CcSEcCtD
Trazodone—Dyspnoea—Etoposide—urinary bladder cancer	0.000388	0.000946	CcSEcCtD
Trazodone—Somnolence—Etoposide—urinary bladder cancer	0.000387	0.000943	CcSEcCtD
Trazodone—Vomiting—Thiotepa—urinary bladder cancer	0.000385	0.000939	CcSEcCtD
Trazodone—Drowsiness—Epirubicin—urinary bladder cancer	0.000382	0.000932	CcSEcCtD
Trazodone—Rash—Thiotepa—urinary bladder cancer	0.000382	0.000931	CcSEcCtD
Trazodone—Dermatitis—Thiotepa—urinary bladder cancer	0.000382	0.00093	CcSEcCtD
Trazodone—Headache—Thiotepa—urinary bladder cancer	0.000379	0.000925	CcSEcCtD
Trazodone—Decreased appetite—Etoposide—urinary bladder cancer	0.000378	0.000922	CcSEcCtD
Trazodone—Body temperature increased—Cisplatin—urinary bladder cancer	0.000375	0.000915	CcSEcCtD
Trazodone—Fatigue—Etoposide—urinary bladder cancer	0.000375	0.000915	CcSEcCtD
Trazodone—Jaundice—Epirubicin—urinary bladder cancer	0.000373	0.000909	CcSEcCtD
Trazodone—Pain—Etoposide—urinary bladder cancer	0.000372	0.000907	CcSEcCtD
Trazodone—Constipation—Etoposide—urinary bladder cancer	0.000372	0.000907	CcSEcCtD
Trazodone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000369	0.0009	CcSEcCtD
Trazodone—Sweating—Epirubicin—urinary bladder cancer	0.000367	0.000894	CcSEcCtD
Trazodone—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000367	0.000894	CcSEcCtD
Trazodone—Asthenia—Gemcitabine—urinary bladder cancer	0.000366	0.000891	CcSEcCtD
Trazodone—Haematuria—Epirubicin—urinary bladder cancer	0.000365	0.000889	CcSEcCtD
Trazodone—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000362	0.000883	CcSEcCtD
Trazodone—Weight increased—Doxorubicin—urinary bladder cancer	0.000361	0.00088	CcSEcCtD
Trazodone—Pruritus—Gemcitabine—urinary bladder cancer	0.000361	0.000879	CcSEcCtD
Trazodone—Nausea—Thiotepa—urinary bladder cancer	0.00036	0.000877	CcSEcCtD
Trazodone—Weight decreased—Doxorubicin—urinary bladder cancer	0.000359	0.000875	CcSEcCtD
Trazodone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000359	0.000874	CcSEcCtD
Trazodone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000356	0.000867	CcSEcCtD
Trazodone—Pruritus—Fluorouracil—urinary bladder cancer	0.000354	0.000864	CcSEcCtD
Trazodone—Drowsiness—Doxorubicin—urinary bladder cancer	0.000354	0.000863	CcSEcCtD
Trazodone—Visual impairment—Methotrexate—urinary bladder cancer	0.000354	0.000862	CcSEcCtD
Trazodone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00035	0.000853	CcSEcCtD
Trazodone—Bradycardia—Epirubicin—urinary bladder cancer	0.00035	0.000852	CcSEcCtD
Trazodone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000349	0.00085	CcSEcCtD
Trazodone—Urticaria—Etoposide—urinary bladder cancer	0.000346	0.000843	CcSEcCtD
Trazodone—Jaundice—Doxorubicin—urinary bladder cancer	0.000345	0.000841	CcSEcCtD
Trazodone—Abdominal pain—Etoposide—urinary bladder cancer	0.000344	0.000839	CcSEcCtD
Trazodone—Body temperature increased—Etoposide—urinary bladder cancer	0.000344	0.000839	CcSEcCtD
Trazodone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000343	0.000836	CcSEcCtD
Trazodone—ABCB1—lymph node—urinary bladder cancer	0.000342	0.00471	CbGeAlD
Trazodone—Tinnitus—Methotrexate—urinary bladder cancer	0.000342	0.000834	CcSEcCtD
Trazodone—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000342	0.000833	CcSEcCtD
Trazodone—Asthenia—Cisplatin—urinary bladder cancer	0.000341	0.000831	CcSEcCtD
Trazodone—Sweating—Doxorubicin—urinary bladder cancer	0.000339	0.000827	CcSEcCtD
Trazodone—Haematuria—Doxorubicin—urinary bladder cancer	0.000337	0.000823	CcSEcCtD
Trazodone—Dizziness—Fluorouracil—urinary bladder cancer	0.000331	0.000808	CcSEcCtD
Trazodone—Visual impairment—Epirubicin—urinary bladder cancer	0.000331	0.000807	CcSEcCtD
Trazodone—Chills—Methotrexate—urinary bladder cancer	0.000329	0.000802	CcSEcCtD
Trazodone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000325	0.000792	CcSEcCtD
Trazodone—Alopecia—Methotrexate—urinary bladder cancer	0.000324	0.00079	CcSEcCtD
Trazodone—Vomiting—Gemcitabine—urinary bladder cancer	0.000324	0.00079	CcSEcCtD
Trazodone—Bradycardia—Doxorubicin—urinary bladder cancer	0.000323	0.000788	CcSEcCtD
Trazodone—Rash—Gemcitabine—urinary bladder cancer	0.000321	0.000783	CcSEcCtD
Trazodone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000321	0.000783	CcSEcCtD
Trazodone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000321	0.000782	CcSEcCtD
Trazodone—Tinnitus—Epirubicin—urinary bladder cancer	0.00032	0.00078	CcSEcCtD
Trazodone—Headache—Gemcitabine—urinary bladder cancer	0.000319	0.000778	CcSEcCtD
Trazodone—Flushing—Epirubicin—urinary bladder cancer	0.000319	0.000777	CcSEcCtD
Trazodone—Vomiting—Fluorouracil—urinary bladder cancer	0.000319	0.000777	CcSEcCtD
Trazodone—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000316	0.000771	CcSEcCtD
Trazodone—Rash—Fluorouracil—urinary bladder cancer	0.000316	0.00077	CcSEcCtD
Trazodone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000316	0.000769	CcSEcCtD
Trazodone—Headache—Fluorouracil—urinary bladder cancer	0.000314	0.000765	CcSEcCtD
Trazodone—Dysgeusia—Methotrexate—urinary bladder cancer	0.000313	0.000762	CcSEcCtD
Trazodone—Asthenia—Etoposide—urinary bladder cancer	0.000312	0.000761	CcSEcCtD
Trazodone—Back pain—Methotrexate—urinary bladder cancer	0.000309	0.000753	CcSEcCtD
Trazodone—Chills—Epirubicin—urinary bladder cancer	0.000308	0.000751	CcSEcCtD
Trazodone—Pruritus—Etoposide—urinary bladder cancer	0.000308	0.00075	CcSEcCtD
Trazodone—Arrhythmia—Epirubicin—urinary bladder cancer	0.000307	0.000748	CcSEcCtD
Trazodone—Visual impairment—Doxorubicin—urinary bladder cancer	0.000306	0.000746	CcSEcCtD
Trazodone—Alopecia—Epirubicin—urinary bladder cancer	0.000303	0.00074	CcSEcCtD
Trazodone—Nausea—Gemcitabine—urinary bladder cancer	0.000303	0.000738	CcSEcCtD
Trazodone—Vomiting—Cisplatin—urinary bladder cancer	0.000302	0.000736	CcSEcCtD
Trazodone—Vision blurred—Methotrexate—urinary bladder cancer	0.000301	0.000734	CcSEcCtD
Trazodone—Rash—Cisplatin—urinary bladder cancer	0.000299	0.00073	CcSEcCtD
Trazodone—Dermatitis—Cisplatin—urinary bladder cancer	0.000299	0.000729	CcSEcCtD
Trazodone—Diarrhoea—Etoposide—urinary bladder cancer	0.000298	0.000726	CcSEcCtD
Trazodone—Nausea—Fluorouracil—urinary bladder cancer	0.000298	0.000725	CcSEcCtD
Trazodone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000296	0.000722	CcSEcCtD
Trazodone—Tinnitus—Doxorubicin—urinary bladder cancer	0.000296	0.000722	CcSEcCtD
Trazodone—Anaemia—Methotrexate—urinary bladder cancer	0.000295	0.00072	CcSEcCtD
Trazodone—Flushing—Doxorubicin—urinary bladder cancer	0.000295	0.000719	CcSEcCtD
Trazodone—Flatulence—Epirubicin—urinary bladder cancer	0.000294	0.000718	CcSEcCtD
Trazodone—Tension—Epirubicin—urinary bladder cancer	0.000293	0.000715	CcSEcCtD
Trazodone—Dysgeusia—Epirubicin—urinary bladder cancer	0.000293	0.000713	CcSEcCtD
Trazodone—Nervousness—Epirubicin—urinary bladder cancer	0.00029	0.000708	CcSEcCtD
Trazodone—Back pain—Epirubicin—urinary bladder cancer	0.000289	0.000705	CcSEcCtD
Trazodone—Malaise—Methotrexate—urinary bladder cancer	0.000288	0.000702	CcSEcCtD
Trazodone—Dizziness—Etoposide—urinary bladder cancer	0.000288	0.000701	CcSEcCtD
Trazodone—Vertigo—Methotrexate—urinary bladder cancer	0.000287	0.000699	CcSEcCtD
Trazodone—Chills—Doxorubicin—urinary bladder cancer	0.000285	0.000695	CcSEcCtD
Trazodone—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000284	0.000692	CcSEcCtD
Trazodone—Nausea—Cisplatin—urinary bladder cancer	0.000282	0.000688	CcSEcCtD
Trazodone—Vision blurred—Epirubicin—urinary bladder cancer	0.000282	0.000687	CcSEcCtD
Trazodone—Alopecia—Doxorubicin—urinary bladder cancer	0.000281	0.000684	CcSEcCtD
Trazodone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000277	0.000676	CcSEcCtD
Trazodone—Vomiting—Etoposide—urinary bladder cancer	0.000277	0.000674	CcSEcCtD
Trazodone—Anaemia—Epirubicin—urinary bladder cancer	0.000276	0.000673	CcSEcCtD
Trazodone—Agitation—Epirubicin—urinary bladder cancer	0.000275	0.00067	CcSEcCtD
Trazodone—Rash—Etoposide—urinary bladder cancer	0.000274	0.000669	CcSEcCtD
Trazodone—Dermatitis—Etoposide—urinary bladder cancer	0.000274	0.000668	CcSEcCtD
Trazodone—Headache—Etoposide—urinary bladder cancer	0.000273	0.000665	CcSEcCtD
Trazodone—Flatulence—Doxorubicin—urinary bladder cancer	0.000272	0.000664	CcSEcCtD
Trazodone—Arthralgia—Methotrexate—urinary bladder cancer	0.000272	0.000663	CcSEcCtD
Trazodone—Chest pain—Methotrexate—urinary bladder cancer	0.000272	0.000663	CcSEcCtD
Trazodone—Myalgia—Methotrexate—urinary bladder cancer	0.000272	0.000663	CcSEcCtD
Trazodone—Tension—Doxorubicin—urinary bladder cancer	0.000271	0.000662	CcSEcCtD
Trazodone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000271	0.00066	CcSEcCtD
Trazodone—Malaise—Epirubicin—urinary bladder cancer	0.00027	0.000657	CcSEcCtD
Trazodone—Discomfort—Methotrexate—urinary bladder cancer	0.000269	0.000655	CcSEcCtD
Trazodone—Nervousness—Doxorubicin—urinary bladder cancer	0.000269	0.000655	CcSEcCtD
Trazodone—Vertigo—Epirubicin—urinary bladder cancer	0.000269	0.000655	CcSEcCtD
Trazodone—Syncope—Epirubicin—urinary bladder cancer	0.000268	0.000653	CcSEcCtD
Trazodone—Back pain—Doxorubicin—urinary bladder cancer	0.000267	0.000652	CcSEcCtD
Trazodone—Palpitations—Epirubicin—urinary bladder cancer	0.000264	0.000644	CcSEcCtD
Trazodone—Confusional state—Methotrexate—urinary bladder cancer	0.000263	0.000641	CcSEcCtD
Trazodone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000263	0.00064	CcSEcCtD
Trazodone—Vision blurred—Doxorubicin—urinary bladder cancer	0.000261	0.000635	CcSEcCtD
Trazodone—Nausea—Etoposide—urinary bladder cancer	0.000258	0.00063	CcSEcCtD
Trazodone—Hypertension—Epirubicin—urinary bladder cancer	0.000258	0.000629	CcSEcCtD
Trazodone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000257	0.000625	CcSEcCtD
Trazodone—Anaemia—Doxorubicin—urinary bladder cancer	0.000256	0.000623	CcSEcCtD
Trazodone—Arthralgia—Epirubicin—urinary bladder cancer	0.000254	0.00062	CcSEcCtD
Trazodone—Myalgia—Epirubicin—urinary bladder cancer	0.000254	0.00062	CcSEcCtD
Trazodone—Chest pain—Epirubicin—urinary bladder cancer	0.000254	0.00062	CcSEcCtD
Trazodone—Agitation—Doxorubicin—urinary bladder cancer	0.000254	0.00062	CcSEcCtD
Trazodone—Anxiety—Epirubicin—urinary bladder cancer	0.000254	0.000618	CcSEcCtD
Trazodone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000252	0.000614	CcSEcCtD
Trazodone—Discomfort—Epirubicin—urinary bladder cancer	0.000251	0.000613	CcSEcCtD
Trazodone—Malaise—Doxorubicin—urinary bladder cancer	0.000249	0.000608	CcSEcCtD
Trazodone—Dry mouth—Epirubicin—urinary bladder cancer	0.000249	0.000607	CcSEcCtD
Trazodone—Vertigo—Doxorubicin—urinary bladder cancer	0.000248	0.000606	CcSEcCtD
Trazodone—Anorexia—Methotrexate—urinary bladder cancer	0.000248	0.000606	CcSEcCtD
Trazodone—Syncope—Doxorubicin—urinary bladder cancer	0.000248	0.000605	CcSEcCtD
Trazodone—Confusional state—Epirubicin—urinary bladder cancer	0.000246	0.0006	CcSEcCtD
Trazodone—Palpitations—Doxorubicin—urinary bladder cancer	0.000244	0.000596	CcSEcCtD
Trazodone—Oedema—Epirubicin—urinary bladder cancer	0.000244	0.000595	CcSEcCtD
Trazodone—Hypotension—Methotrexate—urinary bladder cancer	0.000244	0.000594	CcSEcCtD
Trazodone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000243	0.000593	CcSEcCtD
Trazodone—Shock—Epirubicin—urinary bladder cancer	0.00024	0.000585	CcSEcCtD
Trazodone—Hypertension—Doxorubicin—urinary bladder cancer	0.000239	0.000582	CcSEcCtD
Trazodone—Tachycardia—Epirubicin—urinary bladder cancer	0.000238	0.00058	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000237	0.000579	CcSEcCtD
Trazodone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000236	0.000575	CcSEcCtD
Trazodone—Insomnia—Methotrexate—urinary bladder cancer	0.000236	0.000575	CcSEcCtD
Trazodone—Chest pain—Doxorubicin—urinary bladder cancer	0.000235	0.000574	CcSEcCtD
Trazodone—Myalgia—Doxorubicin—urinary bladder cancer	0.000235	0.000574	CcSEcCtD
Trazodone—Arthralgia—Doxorubicin—urinary bladder cancer	0.000235	0.000574	CcSEcCtD
Trazodone—Anxiety—Doxorubicin—urinary bladder cancer	0.000235	0.000572	CcSEcCtD
Trazodone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000234	0.000571	CcSEcCtD
Trazodone—Discomfort—Doxorubicin—urinary bladder cancer	0.000233	0.000567	CcSEcCtD
Trazodone—Anorexia—Epirubicin—urinary bladder cancer	0.000233	0.000567	CcSEcCtD
Trazodone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000232	0.000566	CcSEcCtD
Trazodone—Somnolence—Methotrexate—urinary bladder cancer	0.000232	0.000565	CcSEcCtD
Trazodone—Dry mouth—Doxorubicin—urinary bladder cancer	0.00023	0.000561	CcSEcCtD
Trazodone—Hypotension—Epirubicin—urinary bladder cancer	0.000228	0.000556	CcSEcCtD
Trazodone—Confusional state—Doxorubicin—urinary bladder cancer	0.000228	0.000555	CcSEcCtD
Trazodone—Decreased appetite—Methotrexate—urinary bladder cancer	0.000227	0.000552	CcSEcCtD
Trazodone—Oedema—Doxorubicin—urinary bladder cancer	0.000226	0.00055	CcSEcCtD
Trazodone—Fatigue—Methotrexate—urinary bladder cancer	0.000225	0.000548	CcSEcCtD
Trazodone—Pain—Methotrexate—urinary bladder cancer	0.000223	0.000543	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000222	0.000542	CcSEcCtD
Trazodone—Shock—Doxorubicin—urinary bladder cancer	0.000222	0.000541	CcSEcCtD
Trazodone—Insomnia—Epirubicin—urinary bladder cancer	0.000221	0.000538	CcSEcCtD
Trazodone—Tachycardia—Doxorubicin—urinary bladder cancer	0.00022	0.000537	CcSEcCtD
Trazodone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000219	0.000534	CcSEcCtD
Trazodone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000218	0.000532	CcSEcCtD
Trazodone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000217	0.00053	CcSEcCtD
Trazodone—Somnolence—Epirubicin—urinary bladder cancer	0.000217	0.000529	CcSEcCtD
Trazodone—Anorexia—Doxorubicin—urinary bladder cancer	0.000215	0.000524	CcSEcCtD
Trazodone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000215	0.000524	CcSEcCtD
Trazodone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000213	0.00052	CcSEcCtD
Trazodone—Decreased appetite—Epirubicin—urinary bladder cancer	0.000212	0.000517	CcSEcCtD
Trazodone—Hypotension—Doxorubicin—urinary bladder cancer	0.000211	0.000514	CcSEcCtD
Trazodone—Fatigue—Epirubicin—urinary bladder cancer	0.00021	0.000513	CcSEcCtD
Trazodone—Pain—Epirubicin—urinary bladder cancer	0.000209	0.000508	CcSEcCtD
Trazodone—Constipation—Epirubicin—urinary bladder cancer	0.000209	0.000508	CcSEcCtD
Trazodone—Urticaria—Methotrexate—urinary bladder cancer	0.000207	0.000505	CcSEcCtD
Trazodone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000206	0.000502	CcSEcCtD
Trazodone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000206	0.000502	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000206	0.000501	CcSEcCtD
Trazodone—Insomnia—Doxorubicin—urinary bladder cancer	0.000204	0.000498	CcSEcCtD
Trazodone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000203	0.000494	CcSEcCtD
Trazodone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000201	0.000491	CcSEcCtD
Trazodone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000201	0.00049	CcSEcCtD
Trazodone—Somnolence—Doxorubicin—urinary bladder cancer	0.000201	0.000489	CcSEcCtD
Trazodone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000199	0.000486	CcSEcCtD
Trazodone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000196	0.000478	CcSEcCtD
Trazodone—Fatigue—Doxorubicin—urinary bladder cancer	0.000195	0.000474	CcSEcCtD
Trazodone—Urticaria—Epirubicin—urinary bladder cancer	0.000194	0.000472	CcSEcCtD
Trazodone—Pain—Doxorubicin—urinary bladder cancer	0.000193	0.00047	CcSEcCtD
Trazodone—Constipation—Doxorubicin—urinary bladder cancer	0.000193	0.00047	CcSEcCtD
Trazodone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000193	0.00047	CcSEcCtD
Trazodone—Body temperature increased—Epirubicin—urinary bladder cancer	0.000193	0.00047	CcSEcCtD
Trazodone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000192	0.000468	CcSEcCtD
Trazodone—Asthenia—Methotrexate—urinary bladder cancer	0.000187	0.000456	CcSEcCtD
Trazodone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000186	0.000453	CcSEcCtD
Trazodone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000185	0.00045	CcSEcCtD
Trazodone—Pruritus—Methotrexate—urinary bladder cancer	0.000184	0.00045	CcSEcCtD
Trazodone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00018	0.000438	CcSEcCtD
Trazodone—Urticaria—Doxorubicin—urinary bladder cancer	0.000179	0.000437	CcSEcCtD
Trazodone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000178	0.000435	CcSEcCtD
Trazodone—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000178	0.000435	CcSEcCtD
Trazodone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000178	0.000435	CcSEcCtD
Trazodone—Asthenia—Epirubicin—urinary bladder cancer	0.000175	0.000427	CcSEcCtD
Trazodone—Pruritus—Epirubicin—urinary bladder cancer	0.000173	0.000421	CcSEcCtD
Trazodone—Dizziness—Methotrexate—urinary bladder cancer	0.000172	0.00042	CcSEcCtD
Trazodone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000167	0.000407	CcSEcCtD
Trazodone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000166	0.000405	CcSEcCtD
Trazodone—Vomiting—Methotrexate—urinary bladder cancer	0.000166	0.000404	CcSEcCtD
Trazodone—Rash—Methotrexate—urinary bladder cancer	0.000164	0.000401	CcSEcCtD
Trazodone—Dermatitis—Methotrexate—urinary bladder cancer	0.000164	0.0004	CcSEcCtD
Trazodone—Headache—Methotrexate—urinary bladder cancer	0.000163	0.000398	CcSEcCtD
Trazodone—Asthenia—Doxorubicin—urinary bladder cancer	0.000162	0.000395	CcSEcCtD
Trazodone—Dizziness—Epirubicin—urinary bladder cancer	0.000161	0.000393	CcSEcCtD
Trazodone—Pruritus—Doxorubicin—urinary bladder cancer	0.00016	0.000389	CcSEcCtD
Trazodone—Vomiting—Epirubicin—urinary bladder cancer	0.000155	0.000378	CcSEcCtD
Trazodone—Nausea—Methotrexate—urinary bladder cancer	0.000155	0.000377	CcSEcCtD
Trazodone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000154	0.000376	CcSEcCtD
Trazodone—Rash—Epirubicin—urinary bladder cancer	0.000154	0.000375	CcSEcCtD
Trazodone—Dermatitis—Epirubicin—urinary bladder cancer	0.000154	0.000375	CcSEcCtD
Trazodone—Headache—Epirubicin—urinary bladder cancer	0.000153	0.000373	CcSEcCtD
Trazodone—Dizziness—Doxorubicin—urinary bladder cancer	0.000149	0.000364	CcSEcCtD
Trazodone—Nausea—Epirubicin—urinary bladder cancer	0.000145	0.000353	CcSEcCtD
Trazodone—Vomiting—Doxorubicin—urinary bladder cancer	0.000143	0.00035	CcSEcCtD
Trazodone—Rash—Doxorubicin—urinary bladder cancer	0.000142	0.000347	CcSEcCtD
Trazodone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000142	0.000347	CcSEcCtD
Trazodone—Headache—Doxorubicin—urinary bladder cancer	0.000141	0.000345	CcSEcCtD
Trazodone—Nausea—Doxorubicin—urinary bladder cancer	0.000134	0.000327	CcSEcCtD
Trazodone—HTR1A—Signaling Pathways—TERT—urinary bladder cancer	1.59e-05	0.000258	CbGpPWpGaD
Trazodone—HTR2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.59e-05	0.000258	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—IL2—urinary bladder cancer	1.58e-05	0.000258	CbGpPWpGaD
Trazodone—HRH1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.58e-05	0.000257	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—TERT—urinary bladder cancer	1.58e-05	0.000257	CbGpPWpGaD
Trazodone—ADRA2A—Hemostasis—KRAS—urinary bladder cancer	1.58e-05	0.000256	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—S100B—urinary bladder cancer	1.57e-05	0.000256	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.57e-05	0.000255	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—NCOR1—urinary bladder cancer	1.56e-05	0.000253	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.55e-05	0.000252	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—NCOR1—urinary bladder cancer	1.55e-05	0.000252	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.55e-05	0.000252	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.55e-05	0.000252	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—PPARG—urinary bladder cancer	1.54e-05	0.00025	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—CREBBP—urinary bladder cancer	1.53e-05	0.000249	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.53e-05	0.000248	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—NCOR1—urinary bladder cancer	1.52e-05	0.000248	CbGpPWpGaD
Trazodone—HTR2A—GPCR downstream signaling—IL2—urinary bladder cancer	1.52e-05	0.000246	CbGpPWpGaD
Trazodone—HRH1—GPCR downstream signaling—IL2—urinary bladder cancer	1.51e-05	0.000246	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—IGF1—urinary bladder cancer	1.51e-05	0.000245	CbGpPWpGaD
Trazodone—HTR2B—Signaling by GPCR—EGFR—urinary bladder cancer	1.5e-05	0.000244	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—MTHFR—urinary bladder cancer	1.5e-05	0.000243	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—RHOA—urinary bladder cancer	1.49e-05	0.000243	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.49e-05	0.000241	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—IL2—urinary bladder cancer	1.48e-05	0.000241	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	1.48e-05	0.00024	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.46e-05	0.000237	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.46e-05	0.000237	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—FGFR3—urinary bladder cancer	1.46e-05	0.000237	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—FGFR3—urinary bladder cancer	1.45e-05	0.000236	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.44e-05	0.000235	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.44e-05	0.000234	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.44e-05	0.000234	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.44e-05	0.000234	CbGpPWpGaD
Trazodone—HTR2B—Signaling by GPCR—KRAS—urinary bladder cancer	1.42e-05	0.000231	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—NCOR1—urinary bladder cancer	1.42e-05	0.00023	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—ESR1—urinary bladder cancer	1.41e-05	0.00023	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.41e-05	0.000229	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—ESR1—urinary bladder cancer	1.41e-05	0.000229	CbGpPWpGaD
Trazodone—ADRA2A—Hemostasis—TP53—urinary bladder cancer	1.4e-05	0.000228	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—RHOA—urinary bladder cancer	1.38e-05	0.000225	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—IL2—urinary bladder cancer	1.38e-05	0.000224	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—IL2—urinary bladder cancer	1.38e-05	0.000224	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—IL2—urinary bladder cancer	1.37e-05	0.000223	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—TERT—urinary bladder cancer	1.37e-05	0.000223	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.37e-05	0.000223	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—TERT—urinary bladder cancer	1.37e-05	0.000222	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—IL2—urinary bladder cancer	1.35e-05	0.000219	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—TERT—urinary bladder cancer	1.34e-05	0.000218	CbGpPWpGaD
Trazodone—ADRA2A—Hemostasis—HRAS—urinary bladder cancer	1.34e-05	0.000218	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.31e-05	0.000213	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—ERBB2—urinary bladder cancer	1.28e-05	0.000208	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.27e-05	0.000207	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.26e-05	0.000205	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—FGFR3—urinary bladder cancer	1.26e-05	0.000205	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	1.26e-05	0.000204	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—IL2—urinary bladder cancer	1.25e-05	0.000204	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—TERT—urinary bladder cancer	1.25e-05	0.000203	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.24e-05	0.000202	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CREBBP—urinary bladder cancer	1.23e-05	0.000201	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—FGFR3—urinary bladder cancer	1.23e-05	0.0002	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—IGF1—urinary bladder cancer	1.22e-05	0.000199	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—ESR1—urinary bladder cancer	1.22e-05	0.000199	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	1.22e-05	0.000198	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—EGFR—urinary bladder cancer	1.22e-05	0.000198	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—IGF1—urinary bladder cancer	1.22e-05	0.000198	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—CXCL8—urinary bladder cancer	1.21e-05	0.000197	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PPARG—urinary bladder cancer	1.21e-05	0.000197	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—EGFR—urinary bladder cancer	1.21e-05	0.000197	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.21e-05	0.000197	CbGpPWpGaD
Trazodone—HTR2B—Signaling by GPCR—HRAS—urinary bladder cancer	1.21e-05	0.000196	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.2e-05	0.000195	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—ESR1—urinary bladder cancer	1.2e-05	0.000195	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.18e-05	0.000193	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.17e-05	0.00019	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.17e-05	0.00019	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.17e-05	0.00019	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.17e-05	0.00019	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	1.17e-05	0.000189	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—IL2—urinary bladder cancer	1.16e-05	0.000189	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.15e-05	0.000187	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	1.14e-05	0.000186	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	1.14e-05	0.000186	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.13e-05	0.000184	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—CCND1—urinary bladder cancer	1.13e-05	0.000184	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	1.12e-05	0.000182	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.12e-05	0.000182	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.12e-05	0.000181	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	1.12e-05	0.000181	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	1.11e-05	0.000181	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.11e-05	0.000181	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.1e-05	0.000179	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.1e-05	0.000179	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.1e-05	0.000179	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MMP9—urinary bladder cancer	1.1e-05	0.000179	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.09e-05	0.000178	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—PTEN—urinary bladder cancer	1.09e-05	0.000177	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.07e-05	0.000174	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	1.07e-05	0.000174	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.07e-05	0.000174	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	1.06e-05	0.000172	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.06e-05	0.000172	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	1.06e-05	0.000172	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.05e-05	0.000172	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.05e-05	0.000171	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	1.05e-05	0.000171	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.05e-05	0.00017	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—EP300—urinary bladder cancer	1.04e-05	0.000169	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.04e-05	0.000169	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.04e-05	0.000169	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	1.04e-05	0.000168	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.03e-05	0.000168	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	1.03e-05	0.000168	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	1.03e-05	0.000168	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	1.01e-05	0.000165	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.01e-05	0.000164	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	9.94e-06	0.000162	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	9.92e-06	0.000161	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	9.84e-06	0.00016	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	9.79e-06	0.000159	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	9.78e-06	0.000159	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	9.75e-06	0.000158	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	9.74e-06	0.000158	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	9.73e-06	0.000158	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	9.73e-06	0.000158	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	9.69e-06	0.000158	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	9.67e-06	0.000157	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	9.62e-06	0.000156	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	9.57e-06	0.000156	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	9.54e-06	0.000155	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	9.49e-06	0.000154	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	9.41e-06	0.000153	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.41e-06	0.000153	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	9.36e-06	0.000152	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	9.17e-06	0.000149	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	9.12e-06	0.000148	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	9.07e-06	0.000148	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	9.04e-06	0.000147	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	8.97e-06	0.000146	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	8.95e-06	0.000146	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	8.9e-06	0.000145	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	8.87e-06	0.000144	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	8.87e-06	0.000144	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	8.86e-06	0.000144	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	8.85e-06	0.000144	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	8.83e-06	0.000144	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	8.81e-06	0.000143	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	8.81e-06	0.000143	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	8.78e-06	0.000143	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	8.74e-06	0.000142	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	8.5e-06	0.000138	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	8.49e-06	0.000138	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	8.45e-06	0.000137	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	8.44e-06	0.000137	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	8.43e-06	0.000137	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	8.4e-06	0.000137	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.39e-06	0.000136	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	8.38e-06	0.000136	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	8.33e-06	0.000135	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PTEN—urinary bladder cancer	8.32e-06	0.000135	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	8.27e-06	0.000135	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	8.21e-06	0.000133	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	8.17e-06	0.000133	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	8.16e-06	0.000133	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	8.13e-06	0.000132	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—IL2—urinary bladder cancer	8.11e-06	0.000132	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	8.06e-06	0.000131	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	7.96e-06	0.000129	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—EP300—urinary bladder cancer	7.94e-06	0.000129	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	7.92e-06	0.000129	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	7.91e-06	0.000129	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	7.9e-06	0.000129	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.85e-06	0.000128	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	7.76e-06	0.000126	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	7.74e-06	0.000126	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	7.69e-06	0.000125	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	7.69e-06	0.000125	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	7.68e-06	0.000125	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	7.66e-06	0.000125	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.65e-06	0.000124	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	7.65e-06	0.000124	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	7.63e-06	0.000124	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PTEN—urinary bladder cancer	7.62e-06	0.000124	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	7.59e-06	0.000123	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	7.53e-06	0.000122	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	7.5e-06	0.000122	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	7.49e-06	0.000122	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	7.45e-06	0.000121	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	7.39e-06	0.00012	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	7.36e-06	0.00012	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	7.32e-06	0.000119	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.29e-06	0.000119	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	7.29e-06	0.000119	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—EP300—urinary bladder cancer	7.28e-06	0.000118	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—EP300—urinary bladder cancer	7.27e-06	0.000118	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.21e-06	0.000117	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.21e-06	0.000117	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	7.21e-06	0.000117	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	7.2e-06	0.000117	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	7.16e-06	0.000116	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	7.14e-06	0.000116	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	7.12e-06	0.000116	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	7.09e-06	0.000115	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—SRC—urinary bladder cancer	7.08e-06	0.000115	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	7e-06	0.000114	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.97e-06	0.000113	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	6.96e-06	0.000113	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	6.94e-06	0.000113	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.9e-06	0.000112	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	6.8e-06	0.000111	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.78e-06	0.00011	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	6.76e-06	0.00011	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	6.64e-06	0.000108	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.6e-06	0.000107	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	6.45e-06	0.000105	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.37e-06	0.000104	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	6.36e-06	0.000103	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MYC—urinary bladder cancer	6.34e-06	0.000103	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	6.22e-06	0.000101	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	6.22e-06	0.000101	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	6.22e-06	0.000101	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	6.2e-06	0.000101	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	6.09e-06	9.9e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	6.04e-06	9.82e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	6.01e-06	9.77e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	5.87e-06	9.55e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	5.86e-06	9.53e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	5.78e-06	9.4e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	5.78e-06	9.39e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.75e-06	9.36e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	5.75e-06	9.35e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	5.75e-06	9.35e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	5.66e-06	9.2e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—EP300—urinary bladder cancer	5.49e-06	8.92e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	5.42e-06	8.82e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	5.34e-06	8.69e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	5.22e-06	8.49e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—TP53—urinary bladder cancer	5.21e-06	8.47e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.17e-06	8.41e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.17e-06	8.4e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	5.11e-06	8.31e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	4.99e-06	8.12e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	4.98e-06	8.1e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.96e-06	8.07e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	4.89e-06	7.95e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	4.75e-06	7.72e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	4.54e-06	7.38e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.06e-06	6.61e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.54e-06	5.76e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.38e-06	5.5e-05	CbGpPWpGaD
